Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1)

By afschroeder • August 13, 2026

Wise-Draper TM, Robert C, Wong MK, Middleton MR, Sacco JJ, In GK, Muñoz Couselo E, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Milhem MM, Bowles TL, Tsai KK, Samson A, Harrington KJ, Lebbé C, Gaudy-Marqueste C, Zhu J, Paratala B, Hou JW, Xynos K, Clack A, Coffin RS, Bommareddy PK. Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1). Front Oncol. 2026 Jul 28;16:1798502. doi: 10.3389/fonc.2026.1798502. PMID: 42582160; PMCID: PMC13457113.

Tags: biodistribution and shedding, Hematology/Oncology, HSV-1, oncolytic immunotherapy, PD-1 failed melanoma, Publications, Replimune, RP1, Vusolimogene oderparepvec (RP1)

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma

Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara[...]

Medical Societies in the United States: History, Purpose, Challenge, and Future Directions

Schiller G, Leer LR. Medical Societies in the United States: History, Purpose, Challenge, and Future Directions. Cureus. 2026 Jul 10;18(7):e112407. doi: 10.7759/cureus.112407. PMID: 42572655; PMCID:[...]

Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

Margolis S, Guirguis AN, Lee C, Smith S, LeVee A, Lipsyc-Sharf MD, Bardia A, Sedrak MS. Patient-reported outcomes in clinical trials leading to breast cancer[...]